Alpha 2.0
Login Register
» Journals » Drugs Real World Outcomes

Drugs - Real World Outcomes

Drugs - Real World Outcomes is a scientific journal, published since 2014 in English. The journal's country of origin is Switzerland.
Details
Abbr. Drugs Real World Outcomes
Start 2014
End Continuing
Frequency Quarterly
p-ISSN 2199-1154
e-ISSN 2198-9788
Country Switzerland
Language English
Metrics
h-index / Ranks: 12197 21
SJR / Ranks: 8001 564
CiteScore / Ranks: 8773 2.90
Recent Articles
1.
Long-Term Evaluation of Effectiveness and Immunological Implications of Ocrelizumab in a Real-World Cohort
Guerra T, Caputo F, Bianco A, Paolicelli D, Iaffaldano P
Drugs Real World Outcomes . 2025 Mar; PMID: 40085374
Background And Objectives: Extended follow-up data from real-world cohorts of patients with multiple sclerosis treated with ocrelizumab (OCR) are becoming widely available. This monocentric retrospective study aimed to evaluate the...
2.
Correction: Clinical Significance of Prior Ramucirumab Use on the Effectiveness of Nivolumab as the Third-Line Regimen in Gastric Cancer: A Multicenter Retrospective Study
Obayashi Y, Hirata S, Kono Y, Abe M, Miyahara K, Nakagawa M, et al.
Drugs Real World Outcomes . 2025 Mar; PMID: 40067648
No abstract available.
3.
Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study
Martin C, Malcervelli G, Martinengo G, Levit P, Servienti P, Malaver E, et al.
Drugs Real World Outcomes . 2025 Feb; PMID: 40011377
Background: Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor was licensed for the treatment of ALK-positive metastatic non-small cell lung cancer in 2016. However, real-world evidence on the safety and...
4.
Trends in Reports of Statin-Associated Immune-Mediated Necrotizing Myopathy Using the Japanese Adverse Drug Event Report Database
Takami A, Terashima G, Tajima T, Yamashita K, Igarashi A
Drugs Real World Outcomes . 2025 Jan; 12(1):145-152. PMID: 39890736
Background: In October 2016, precautions of the package inserts for ethical drugs containing statins were revised for immune-mediated necrotizing myopathy (IMNM). Objective: Our objective was to assess the trend in...
5.
Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data
Princic N, Evans K, Shah C, Sing K, Juethner S, Schultz B
Drugs Real World Outcomes . 2025 Jan; 12(1):17-24. PMID: 39875773
Background: Lanadelumab is the only long-term prophylaxis indicated for reduced administration frequency in patients with hereditary angioedema who have been well controlled for > 6 months. Understanding the characteristics of...
6.
Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study
Parhofer K, Bramlage P, Gries C, Harder C, Look C, Paar W, et al.
Drugs Real World Outcomes . 2025 Jan; 12(1):63-74. PMID: 39875772
Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their...
7.
Comparative Efficacy of Lenvatinib Plus Immunotherapy and Regorafenib Plus Immunotherapy After Lenvatinib Failure for Advanced Hepatocellular Carcinoma: A Retrospective Study
Yu Z, Leng B, You R, Diao L, Xu Q, Yin G
Drugs Real World Outcomes . 2025 Jan; 12(1):135-143. PMID: 39833610
Background: The combination of regorafenib and immune checkpoint inhibitor (ICI) has been the most popular second-line systemic therapy for advanced hepatocellular carcinoma (HCC). However, considering the good anti-tumor performance of...
8.
Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA
Jha M, Zhdanava M, Shah A, Voegel A, Tardif-Samson A, Pilon D, et al.
Drugs Real World Outcomes . 2025 Jan; 12(1):35-43. PMID: 39828878
Introduction: Treatment-resistant depression (TRD) is related to disproportionate unemployment and productivity burden in the USA. The current study describes real-world mental health (MH)-related disability days and costs of patients with...
9.
Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study
Fautrel B, Bouhnik Y, Salliot C, Carbonnel F, Fumery M, Bernardeau C, et al.
Drugs Real World Outcomes . 2025 Jan; 12(1):163-164. PMID: 39821191
No abstract available.
10.
Effectiveness and Safety of Vildagliptin Sustained Release in the Management of Type 2 Diabetes Mellitus: Real-World Evidence in Indian Patients [NOVELTY Study]
Sahay R, Bhansali A, Sharma S, Iyer R, Sugumaran A, Mohanasundaram S, et al.
Drugs Real World Outcomes . 2025 Jan; 12(1):83-91. PMID: 39821190
Background And Objective: Vildagliptin sustained release (XR), a formulation that provides vildagliptin 100 mg with a once-daily dose administration, is a recent introduction to manage type 2 diabetes mellitus in...